{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:33:58Z","timestamp":1779165238354,"version":"3.51.4"},"reference-count":30,"publisher":"American Diabetes Association","issue":"5","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,5,1]]},"abstract":"<jats:p>Inflammation and complement activation via the mannose-binding lectin (MBL) pathway have been suggested to play a role in the pathogenesis of diabetic microvascular complications. The association between the complement-activating protein MBL and the development of persistent microalbuminuria was evaluated in an inception cohort of 286 newly diagnosed type 1 diabetic patients consecutively admitted to the Steno Diabetes Center between 1 September 1979 and 31 August 1984. Serum MBL was measured with an immunofluorometric assay in 270 of the patients (159 men) after 3 years of diabetes duration. During the median (range) follow-up period of 18.0 (1.0\u201321.8) years, 75 patients subsequently progressed to persistent micro- or macroalbuminuria (urinary albumin excretion rate &amp;gt;30 mg\/24 h). In patients with MBL levels above the median (1,597 \u03bcg\/l), the cumulative incidence of persistent micro- or macroalbuminuria was 41% (CI 31\u201350) as compared with 26% (CI 17\u201334) in patients with MBL levels below the median (log-rank test, P = 0.003). In a Cox proportional hazard model with sex and age as fixed covariates, MBL was independently associated with later development of persistent micro- or macroalbuminuria (hazard ratio 1.21 [CI 1.02\u20131.42] per 1,000 \u03bcg\/l increase in MBL; P = 0.03) after adjusting for possible confounders. In our study, high levels of MBL early in the course of type 1 diabetes was significantly associated with later development of persistent micro- or macroalbuminuria, suggesting that complement activation initiated by MBL may be involved in the pathogenesis of diabetic microvascular complications.<\/jats:p>","DOI":"10.2337\/diabetes.54.5.1523","type":"journal-article","created":{"date-parts":[[2007,3,6]],"date-time":"2007-03-06T19:04:22Z","timestamp":1173207862000},"page":"1523-1527","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":100,"title":["Mannose-Binding Lectin as a Predictor of Microalbuminuria in Type 1 Diabetes"],"prefix":"10.2337","volume":"54","author":[{"given":"Peter","family":"Hovind","sequence":"first","affiliation":[{"name":"Steno Diabetes Center, Gentofte, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Troels Krarup","family":"Hansen","sequence":"additional","affiliation":[{"name":"Medical Department M (Immunoendocrine Research Unit) and Medical Research Laboratories, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise","family":"Tarnow","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center, Gentofte, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Thiel","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Immunology, University of Aarhus, Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudi","family":"Steffensen","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Aalborg Hospital, Aalborg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan","family":"Flyvbjerg","sequence":"additional","affiliation":[{"name":"Medical Department M (Immunoendocrine Research Unit) and Medical Research Laboratories, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Henrik","family":"Parving","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center, Gentofte, Denmark"},{"name":"Faculty of Health Science, University of Aarhus, Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","reference":[{"key":"2022031218134450500_R1","unstructured":"Parving H-H, Mauer M, Ritz E: Diabetic nephropathy. In The Kidney. Brenner BM, Ed. WB Saunders,2004, p.1777\u20131818"},{"key":"2022031218134450500_R2","doi-asserted-by":"crossref","unstructured":"Bangstad H-J, \u00d8sterby R, Dahl-J\u00f8rgensen K, Berg K, Hartmann A, Nyberg G, Frahm Bj\u00f8rn S, Hanssen KF: Early glomerulopathy is present in young, type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia\u200836:523\u2013529,1993","DOI":"10.1007\/BF02743268"},{"key":"2022031218134450500_R3","doi-asserted-by":"crossref","unstructured":"Saraheimo M, Teppo AM, Forsblom C, Fagerudd J, Groop PH: Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia\u200846:1402\u20131407,2003","DOI":"10.1007\/s00125-003-1194-5"},{"key":"2022031218134450500_R4","doi-asserted-by":"crossref","unstructured":"Hansen TK, Thiel S, Knudsen ST, Gravholt CH, Christiansen JS, Mogensen CE, Poulsen PL: Elevated levels of mannan-binding lectin in patients with type 1 diabetes. J Clin Endocrinol Metab\u200888:4857\u20134861,2003","DOI":"10.1210\/jc.2003-030742"},{"key":"2022031218134450500_R5","doi-asserted-by":"crossref","unstructured":"Hansen TK, Tarnow L, Thiel S, Steffensen R, Stehouwer CD, Schalkwijk CG, Parving HH, Flyvbjerg A: Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes\u200853:1570\u20131576,2004","DOI":"10.2337\/diabetes.53.6.1570"},{"key":"2022031218134450500_R6","doi-asserted-by":"crossref","unstructured":"Uesugi N, Sakata N, Nangaku M, Abe M, Horiuchi S, Hisano S, Iwasaki H: Possible mechanism for medial smooth muscle cell injury in diabetic nephropathy: glycoxidation-mediated local complement activation. Am J Kidney Dis\u200844:224\u2013238,2004","DOI":"10.1053\/j.ajkd.2004.04.027"},{"key":"2022031218134450500_R7","doi-asserted-by":"crossref","unstructured":"Thiel S, Vorup-Jensen T, Stover CM, Schwaeble W, Laursen SB, Poulsen K, Willis AC, Eggleton P, Hansen S, Holmskov U, Reid KB, Jensenius JC: A second serine protease associated with mannan-binding lectin that activates complement. Nature\u2008386:506\u2013510,1997","DOI":"10.1038\/386506a0"},{"key":"2022031218134450500_R8","doi-asserted-by":"crossref","unstructured":"Turner MW: The role of mannose-binding lectin in health and disease. Mol Immunol\u200840:423\u2013429,2003","DOI":"10.1016\/S0161-5890(03)00155-X"},{"key":"2022031218134450500_R9","doi-asserted-by":"crossref","unstructured":"Super M, Thiel S, Lu J, Levinsky RJ, Turner MW: Association of low levels of mannan-binding protein with a common defect of opsonisation. Lancet\u20082:1236\u20131239,1989","DOI":"10.1016\/S0140-6736(89)91849-7"},{"key":"2022031218134450500_R10","doi-asserted-by":"crossref","unstructured":"Petersen SV, Thiel S, Jensenius JC: The mannan-binding lectin pathway of complement activation: biology and disease association. Mol Immunol\u200838:133\u2013149,2001","DOI":"10.1016\/S0161-5890(01)00038-4"},{"key":"2022031218134450500_R11","doi-asserted-by":"crossref","unstructured":"Collard CD, Vakeva A, Morrissey MA, Agah A, Rollins SA, Reenstra WR, Buras JA, Meri S, Stahl GL: Complement activation after oxidative stress: role of the lectin complement pathway. Am J Pathol\u2008156:1549\u20131556,2000","DOI":"10.1016\/S0002-9440(10)65026-2"},{"key":"2022031218134450500_R12","doi-asserted-by":"crossref","unstructured":"Fiane AE, Videm V, Lingaas PS, Heggelund L, Nielsen EW, Geiran OR, Fung M, Mollnes TE: Mechanism of complement activation and its role in the inflammatory response after thoracoabdominal aortic aneurysm repair. Circulation\u2008108:849\u2013856,2003","DOI":"10.1161\/01.CIR.0000084550.16565.01"},{"key":"2022031218134450500_R13","doi-asserted-by":"crossref","unstructured":"Hovind P, Tarnow L, Rossing P, Jensen BR, Graae M, Torp I, Binder C, Parving HH: Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ\u2008328:1105\u20131108,2004","DOI":"10.1136\/bmj.38070.450891.FE"},{"key":"2022031218134450500_R14","doi-asserted-by":"crossref","unstructured":"Hovind P, Tarnow L, Rossing K, Rossing P, Eising S, Larsen N, Binder C, Parving HH: Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care\u200826:1258\u20131264,2003","DOI":"10.2337\/diacare.26.4.1258"},{"key":"2022031218134450500_R15","doi-asserted-by":"crossref","unstructured":"Lizana J, Hellsing K: Polymer enhancement of automated immunotopical nephelometric analysis, as illustrated by determination of urinary albumin. Clin Chem\u200820:415\u2013417,1974","DOI":"10.1093\/clinchem\/20.4.415"},{"key":"2022031218134450500_R16","doi-asserted-by":"crossref","unstructured":"Miles DW, Mogensen CE, Gundersen HJG: Radioimmunoassay for urinary albumin using a single antibody. Scand J Clin Lab Invest\u200826:5\u201311,1970","DOI":"10.3109\/00365517009049206"},{"key":"2022031218134450500_R17","doi-asserted-by":"crossref","unstructured":"Feldt-Rasmussen B, Dinesen B, Deckert M: Enzyme immunoassay: an improved determination of urinary albumin in diabetics with incipient nephropathy. Scand J Clin Lab Invest\u200845:539\u2013544,1985","DOI":"10.3109\/00365518509155256"},{"key":"2022031218134450500_R18","doi-asserted-by":"crossref","unstructured":"Rossing P, Hommel E, Smidt UM, Parving H-H: Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes\u200842:715\u2013719,1993","DOI":"10.2337\/diabetes.42.5.715"},{"key":"2022031218134450500_R19","doi-asserted-by":"crossref","unstructured":"Thiel S, Moller-Kristensen M, Jensen L, Jensenius JC: Assays for the functional activity of the mannan-binding lectin pathway of complement activation. Immunobiology\u2008205:446\u2013454,2002","DOI":"10.1078\/0171-2985-00145"},{"key":"2022031218134450500_R20","doi-asserted-by":"crossref","unstructured":"Hansen TK, Thiel S, Dall R, Rosenfalck AM, Trainer P, Flyvbjerg A, Jorgensen JO, Christiansen JS: GH strongly affects serum concentrations of mannan-binding lectin: evidence for a new IGF-I independent immunomodulatory effect of GH. J Clin Endocrinol Metab\u200886:5383\u20135388,2001","DOI":"10.1210\/jcem.86.11.8009"},{"key":"2022031218134450500_R21","doi-asserted-by":"crossref","unstructured":"Steffensen R, Thiel S, Varming K, Jersild C, Jensenius JC: Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers. J Immunol Methods\u2008241:33\u201342,2000","DOI":"10.1016\/S0022-1759(00)00198-8"},{"key":"2022031218134450500_R22","doi-asserted-by":"crossref","unstructured":"Acosta J, Hettinga J, Fluckiger R, Krumrei N, Goldfine A, Angarita L, Halperin J: Molecular basis for a link between complement and the vascular complications of diabetes. Proc Natl Acad Sci U S A\u200897:5450\u20135455,2000","DOI":"10.1073\/pnas.97.10.5450"},{"key":"2022031218134450500_R23","doi-asserted-by":"crossref","unstructured":"Hsu SI, Couser WG: Chronic progression of tubulointerstitial damage in proteinuric renal disease is mediated by complement activation: a therapeutic role for complement inhibitors?J Am Soc Nephrol\u200814:S186\u2013S191,2003","DOI":"10.1097\/01.ASN.0000070032.58017.20"},{"key":"2022031218134450500_R24","doi-asserted-by":"crossref","unstructured":"Schalkwijk CG, Poland DC, van Dijk W, Kok A, Emeis JJ, Drager AM, Doni A, Van Hinsbergh VW, Stehouwer CD: Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia\u200842:351\u2013357,1999","DOI":"10.1007\/s001250051162"},{"key":"2022031218134450500_R25","doi-asserted-by":"crossref","unstructured":"Saraheimo M, Forsblom C, Hansen TK, Teppo AM, Fagerudd J, Pettersson-Fernholm KJ, Thiel S, Tarnow L, Ebeling P, Flyvbjerg A, Groop PH, on behalf of the FinnDiane Study Group: Increased levels of mannan-binding lectin (MBL) in type 1 diabetic patients with incipient and overt nephropathy. Diabetologia\u200848:198\u2013202,2005","DOI":"10.1007\/s00125-004-1594-1"},{"key":"2022031218134450500_R26","doi-asserted-by":"crossref","unstructured":"Suankratay C, Mold C, Zhang Y, Potempa LA, Lint TF, Gewurz H: Complement regulation in innate immunity and the acute-phase response: inhibition of mannan-binding lectin-initiated complement cytolysis by C-reactive protein (CRP). Clin Exp Immunol\u2008113:353\u2013359,1998","DOI":"10.1046\/j.1365-2249.1998.00663.x"},{"key":"2022031218134450500_R27","doi-asserted-by":"crossref","unstructured":"Borch-Johnsen K, Kreiner S: Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. BMJ\u2008294:1651\u20131654,1987","DOI":"10.1136\/bmj.294.6588.1651"},{"key":"2022031218134450500_R28","doi-asserted-by":"crossref","unstructured":"Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A: Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia\u200832:219\u2013226,1989","DOI":"10.1007\/BF00285287"},{"key":"2022031218134450500_R29","doi-asserted-by":"crossref","unstructured":"Jordan JE, Montalto MC, Stahl GL: Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation\u2008104:1413\u20131418,2001","DOI":"10.1161\/hc3601.095578"},{"key":"2022031218134450500_R30","doi-asserted-by":"crossref","unstructured":"Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG, Rollins S, Todaro TG, Nicolau JC, Ruzyllo W, Armstrong PW: Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation\u2008108:1184\u20131190,2003","DOI":"10.1161\/01.CIR.0000087447.12918.85"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/54\/5\/1523\/380927\/zdb00505001523.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/54\/5\/1523\/380927\/zdb00505001523.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:26:20Z","timestamp":1667406380000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/54\/5\/1523\/25917\/Mannose-Binding-Lectin-as-a-Predictor-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,1]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5,1]]}},"URL":"https:\/\/doi.org\/10.2337\/diabetes.54.5.1523","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5,1]]}}}